#USA #Ann Arbor #lipid nanoparticles #Cayman Chemical #Curapath

Cayman Chemical and Curapath Join Forces

In a groundbreaking collaboration, Cayman Chemical and Curapath have united to provide researchers with greater access to PEG-free shielding lipids, crucial for advancing lipid nanoparticle (LNP) technology. This partnership focuses on producing non-viral drug delivery systems which are essential for sectors like gene therapy, mRNA vaccines, and biologic treatments. As the landscape of medical science continually shifts toward more effective and safer therapies, the development of PEG-free options is increasingly important.

Cayman Chemical, a prominent global supplier known for its high-quality lipids for LNP applications, is teaming up with Curapath, a leader renowned for their expertise in designing and custom manufacturing polymer and lipid-based drug delivery systems. This collaboration not only enhances Cayman's lipid portfolio but also allows researchers to access Curapath's unique shielding lipids, specifically their proprietary polysarcosine (pSar) and polyamino acid-based materials.

Traditionally, PEGylated lipids have been the standard for shielding LNPs from immune detection. However, mounting concerns surrounding the immunogenicity of PEG and its associated adverse reactions have driven the need for safer alternatives. Curapath's pSar lipids represent a response to this demand—a synthetic, biocompatible polymer that offers a non-toxic, biodegradable solution without the risks linked to PEGylated lipids. These innovations can address the critical challenges researchers face, offering a more reliable method of formulating effective LNPs.

Manufactured right at Curapath's headquarters in Valencia, Spain, these cutting-edge pSar lipids can now be seamlessly integrated into various LNP formulations, thanks to Cayman's expansive distribution network. The partnership will not only provide specific polysarcosine but also ensure that other high-quality polymers like poly(lysine) and poly(glutamic acid) are readily available. Moreover, cationic polymers optimized for gene delivery will also enhance the accessibility of critical materials researchers need to make significant advancements.

According to representatives from both companies, this strategic alliance is set to empower scientists around the world, enabling them to develop biocompatible therapies that act effectively without the risks associated with traditional PEGylated lipids. As stated by a spokesperson at Curapath,